CA3160629A1 - Synthetic composition for balancing the bile acid profile in the intestine - Google Patents

Synthetic composition for balancing the bile acid profile in the intestine

Info

Publication number
CA3160629A1
CA3160629A1 CA3160629A CA3160629A CA3160629A1 CA 3160629 A1 CA3160629 A1 CA 3160629A1 CA 3160629 A CA3160629 A CA 3160629A CA 3160629 A CA3160629 A CA 3160629A CA 3160629 A1 CA3160629 A1 CA 3160629A1
Authority
CA
Canada
Prior art keywords
human
bile acids
human milk
ibs
milk oligosaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3160629A
Other languages
English (en)
French (fr)
Inventor
Louise Kristine VIGSNÆS
Bruce Mcconnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycom AS
Original Assignee
Glycom AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom AS filed Critical Glycom AS
Publication of CA3160629A1 publication Critical patent/CA3160629A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3160629A 2019-11-14 2020-11-13 Synthetic composition for balancing the bile acid profile in the intestine Pending CA3160629A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201901337 2019-11-14
DKPA201901337 2019-11-14
PCT/IB2020/060692 WO2021094993A1 (en) 2019-11-14 2020-11-13 Synthetic composition for balancing the bile acid profile in the intestine

Publications (1)

Publication Number Publication Date
CA3160629A1 true CA3160629A1 (en) 2021-05-20

Family

ID=75912919

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3160629A Pending CA3160629A1 (en) 2019-11-14 2020-11-13 Synthetic composition for balancing the bile acid profile in the intestine

Country Status (8)

Country Link
US (1) US20220378809A1 (https=)
EP (1) EP4058031A4 (https=)
JP (1) JP2023501111A (https=)
KR (1) KR20220101131A (https=)
CN (1) CN114728015A (https=)
BR (1) BR112022009214A2 (https=)
CA (1) CA3160629A1 (https=)
WO (1) WO2021094993A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
TW202126317A (zh) 2019-09-24 2021-07-16 美商普拉塔生技公司 用於治療發炎和免疫疾病之組成物和方法
WO2022026415A1 (en) * 2020-07-31 2022-02-03 Abbott Laboratories Method of preventing, reducing or delaying fatty liver disease
WO2022271729A1 (en) * 2021-06-21 2022-12-29 Pendulum Therapeutics, Inc. Compositions comprising microbes and methods of use and making thereof
CN115948273B (zh) * 2022-06-21 2023-07-18 合肥瀚微生物科技有限公司 治疗糖尿病及相关病症的两歧双歧杆菌
WO2024126578A1 (en) * 2022-12-13 2024-06-20 Dsm Ip Assets B.V. Synthetic composition comprising a human milk oligosaccharide for microbiota modulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2735108B1 (en) * 2011-07-22 2016-12-21 Telefonaktiebolaget LM Ericsson (publ) Radio base station, radio network node and methods therein for detecting a faulty antenna
AT515152B1 (de) * 2013-11-26 2015-12-15 Chemiefaser Lenzing Ag Verfahren zum Vorbehandeln von rückgewonnenen Baumwollfasern zur Verwendung bei der Herstellung von Formkörpern aus regenerierter Cellulose
EP3212197A4 (en) * 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US11040049B2 (en) * 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US10987368B2 (en) * 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10751354B2 (en) * 2015-09-14 2020-08-25 Glycom A/S Synthetic composition for microbiota modulation
CN108348536B (zh) * 2015-11-17 2021-09-24 格礼卡姆股份公司 治疗抗生素相关性并发症的合成组合物
WO2017215721A1 (en) * 2016-06-15 2017-12-21 Glycom A/S Synthetic compositions comprising human milk oligosaccharides for use γν the prevention and treatment of disorders
US11278558B2 (en) * 2017-03-01 2022-03-22 Glycom A/S Synthetic composition for microbiota modulation
AU2018250337B2 (en) * 2017-04-07 2024-02-15 Children's Hospital Medical Center Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
CN111587376A (zh) * 2017-09-13 2020-08-25 进化生物系统股份有限公司 哺乳动物婴儿的代谢组学修正
BR112020010843A2 (pt) * 2017-11-30 2020-11-10 Glycom A/S oligossacarídeos do leite humano e composições sintéticas desses para modulação da microbiota

Also Published As

Publication number Publication date
EP4058031A4 (en) 2023-11-08
KR20220101131A (ko) 2022-07-19
WO2021094993A1 (en) 2021-05-20
CN114728015A (zh) 2022-07-08
JP2023501111A (ja) 2023-01-18
BR112022009214A2 (pt) 2022-08-02
US20220378809A1 (en) 2022-12-01
EP4058031A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
US20220378809A1 (en) Synthetic composition for balancing the bile acid profile in the intestine
KR102741265B1 (ko) 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물
US11291677B2 (en) Synthetic composition for microbiota modulation
US11278558B2 (en) Synthetic composition for microbiota modulation
EP3458073B1 (en) Use of human milk oligosaccharides for treating migraine in patients with inflammatory bowel syndrome
US20220233562A1 (en) COMPOSITION COMPRISING HMOs FOR PREVENTING OR REDUCING NOCICEPTION
US11541067B2 (en) HMO compositions and methods for reducing detrimental proteolytic metabolites
US11541069B2 (en) One or more HMOs for reducing or preventing fatigue and/or improving focus or concentration
US11554131B2 (en) Mixture of HMOs for treating autoimmune diseases
EP3897662B1 (en) Composition comprising a human milk oligosaccharide for use in treating humans using low-fodmap diets

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250825

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202